Article Text

Download PDFPDF
Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells
  1. Sara A. Byron, PhD*,
  2. David C. Loch, PhD and
  3. Pamela M. Pollock, PhD
  1. *Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ; and
  2. Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.
  1. Address correspondence and reprint requests to Pamela M. Pollock, PhD, Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60Musk Ave, Kelvin Grove, Queensland 4059, Australia. E-mail: pamela.pollock@qut.edu.au.

Abstract

Objective The fibroblast growth factor (FGF) family of signaling molecules has been associated with chemoresistance and poor prognosis in a number of cancer types, including lung, breast, ovarian, prostate, and head and neck carcinomas. Given the identification of activating mutations in the FGF receptor 2 (FGFR2) receptor tyrosine kinase in a subset of endometrial tumors, agents with activity against FGFRs are currently being tested in clinical trials for recurrent and progressive endometrial cancer. Here, we evaluated the effect of FGFR inhibition on the in vitro efficacy of chemotherapy in endometrial cancer cell lines.

Methods Human endometrial cancer cell lines with wild-type or activating FGFR2 mutations were used to determine any synergism with concurrent use of the pan-FGFR inhibitor, PD173074, and the chemotherapeutics, doxorubicin and paclitaxel, on cell proliferation and apoptosis.

Results FGFR2 mutation status did not alter sensitivity to either chemotherapeutic agent alone. The combination of PD173074 with paclitaxel or doxorubicin showed synergistic activity in the 3 FGFR2 mutant cell lines evaluated. In addition, although nonmutant cell lines were resistant to FGFR inhibition alone, the addition of PD173074 potentiated the cytostatic effect of paclitaxel and doxorubicin in a subset of FGFR2 wild-type endometrial cancer cell lines.

Conclusions Together these data suggest a potential therapeutic benefit to combining an FGFR inhibitor with standard chemotherapeutic agents in endometrial cancer therapy particularly in patients with FGFR2 mutation positive tumors.

  • Endometrial cancer
  • Chemotherapy
  • Synergy
  • FGFR
  • PD173074

Statistics from Altmetric.com

Footnotes

  • This work was supported by a Queensland University of Technology Vice Chancellor’s Senior Research Fellowship (PP), a Sylvia Chase Postdoctoral Fellowship (SAB), and an American Cancer Society Postdoctoral Fellowship (SAB).

  • The authors declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.